Impact of YOGA on the Quality of Life and Well-being of Heart Failure Patients
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 24, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of yoga on the quality of life and overall well-being of patients with chronic heart failure. Heart failure is a long-term condition that can make people feel anxious and depressed, which can affect their treatment and recovery. The trial aims to see if practicing yoga regularly can help improve how patients feel physically and emotionally, as well as enhance their overall health.
To participate, individuals must be at least 18 years old and have chronic heart failure, with their heart function measured at a certain level. They should be stable and have not experienced any serious heart failure episodes in the past month. Participants will engage in yoga sessions, either in person or online, and will need to provide written consent to join. It’s important to note that those who have practiced yoga regularly in the past six months or have certain medical conditions may not be eligible. This study offers a unique opportunity to explore how yoga can complement traditional heart failure treatments and improve daily life for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥18 years old
- • Chronic heart failure patient defined by: Most recent LVEF ≤50% (regardless of measurement method)
- • Stabilized (last episode of acute heart failure dating back more than a month) in NYHA stage I to III dyspnoea, ambulatory, discharged from hospital for \> 1 month
- • Drug treatment optimized according to the judgment of the investigator
- • Ability to participate in activities as proposed (remote or face-to-face)
- • Patient affiliated with a social security scheme
- • Written consent to participate
- Exclusion Criteria:
- • Patients who have practiced yoga regularly (\> once a month) in the six months prior to selection.
- • Current pregnancy / lactation
- • Etiology of heart failure: hypertrophic cardiomyopathy, restrictive heart disease or severe curable valve disease
- • Severe renal impairment GFR\<25ml/min/1.73 m2 or on dialysis.
- • Persons subject to legal protection measures (guardianship, curatorship)
- • Person not "receptive" to the practice of yoga
- • Participation in intervention research
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Lise LEGRAND, Dr
Study Chair
Institut de Cardiologie - Hôpital La Pitié Salpêtrière (APHP)
Gilles MONTALESCOT, Pr
Study Director
Institut de Cardiologie - Hôpital La Pitié Salpêtrière (APHP)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported